Immune responses were observed at all dose levels
SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression HIP-modified primary